UBS
UBS Downgrades QuidelOrtho to Sell
The investment bank cited risks in the firm's guidance for respiratory test sales and in the launch of the Savanna point-of-care MDx system.
UBS Initiates Coverage of Bio-Rad Laboratories, Fulgent Genetics, Bio-Techne
The global financial services firm gave ratings of Buy, Neutral, and Buy to Bio-Rad, Fulgent, and Bio-Techne, respectively.
UBS Initiates Coverage of Bruker With Buy Rating
The bank said factors including Bruker's increasing exposure to consumables and pharma end markets as well as increased US federal funding would drive growth.
Singular Genomics Ups IPO Target to $187M
The San Diego-based DNA sequencing startup plans to offer 8.5 million shares at an IPO price between $20 and $22 per share, for a $1.5 billion valuation.
Sequencing Startup Singular Genomics Files for $100M IPO
The San Diego-based company, led by a raft of Illumina veterans, is planning to build a new sequencing platform to address genomic and multiomic analysis.
May 12, 2016
Sep 20, 2012
Sep 23, 2011
Sep 23, 2010